Form 4: Apogee Therapeutics CFO Executes Stock Sale

Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., sold 2,000 shares of common stock.
• The transaction occurred on April 16, 2026, at a price of $90.00 per share.
• Following the sale, Henderson retains beneficial ownership of 175,371 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal regarding the executive's view on the company's short-term valuation.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common practice for executives in the biotechnology sector to manage personal liquidity and is generally not indicative of a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to divest shares while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the sale was executed under a pre-planned trading arrangement.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, CFO, Equity Sale